Progenika Biopharma SA creates a subsidiary in the UK

22-Jul-2005

Progenika Biopharma SA, an innovative Spanish company developing microarrays for genetic diagnosis, today announced the creation of a new subsidiary, Progenika Biopharma Ltd, to be based in the UK. The UK facility, which it is expected to come on line in Q1 2006, will initially process genetic diagnostic tests developed by the parent company in their headquarters and research facility on the outskirts of Bilbao, Spain.

Progenika Ltd will provide a diagnostic service based on the unique Sendagene(TM) platform for the diagnosis of genetically complex diseases. Dr Laureano Simon, company founder and CEO, underlined the enormous potential of the Sendagene(TM) technology for the early diagnosis of potentially debilitating conditions allowing doctors to treat and control important diseases suffered by their patients such as Familial Hypercholesterolaemia and Inflammatory Bowel Disease. The creation of Progenika Biopharma Ltd brings the possibility of individualized medicine one step closer to reality he said in a statement today.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures